Skadden, Cooley Guide $4.9B Deal For Cancer Drugmaker
Biopharmaceutical giant Gilead Sciences Inc. has agreed to buy cancer-focused biotechnology firm Forty Seven Inc. for about $4.9 billion, the companies said Monday, in a deal stitched together with help from...To view the full article, register now.
Already a subscriber? Click here to view full article